AJANTPHARM
Ajanta Pharma Limited (AJANTPHARM) Stock Analysis
Ajanta Pharma Limited is an Indian pharmaceutical company with a strong presence in branded generics and specialty therapies. It markets products in India and numerous international markets across Africa, Asia, and CIS countries. The company focuses on high-margin differentiated formulations. It is a well-regarded listed mid-cap pharma stock.
Healthcare › Drug Manufacturers - Specialty & Generic
₹3,410.10
-4.77% 1W | +41.10% 52W
Market Cap
42.6k CR
P/E Ratio
37.6
52W High
₹3796
52W Low
₹2380.2
Div. Yield
1.86%
Beta
0.2
50 DMA
₹3549.4
200 DMA
₹3136.6
Profit Margin
19.6%
Inst. Own.
24.3%
⚠️ BREAKDOWN
⚠️ BREAKDOWN
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,021 | 1,028 | 1,105 | 1,054 | 1,145 | 1,187 | 1,146 | 1,170 | 1,303 | 1,354 | 1,375 | 1,422 | 1,626 |
| Expenses | 750 | 738 | 791 | 776 | 815 | 875 | 825 | 873 | 951 | 1,026 | 993 | 1,088 | 1,202 |
| Operating Profit | 271 | 291 | 314 | 278 | 330 | 311 | 321 | 297 | 351 | 328 | 382 | 333 | 424 |
| OPM % | 27% | 28% | 28% | 26% | 29% | 26% | 28% | 25% | 27% | 24% | 28% | 23% | 26% |
| Other Income | 32 | 21 | 14 | 36 | 26 | 19 | 30 | 18 | 26 | 59 | 25 | 61 | 71 |
| Interest | 1 | 2 | 2 | 2 | 1 | 6 | 8 | 6 | 5 | 3 | 5 | 2 | 3 |
| Depreciation | 33 | 34 | 34 | 34 | 34 | 34 | 36 | 40 | 41 | 43 | 44 | 45 | 44 |
| Profit before tax | 269 | 276 | 291 | 278 | 322 | 290 | 307 | 269 | 331 | 341 | 359 | 347 | 447 |
| Tax % | 23% | 29% | 28% | 27% | 24% | 25% | 24% | 16% | 23% | 24% | 24% | 23% | 25% |
| Net Profit | 208 | 195 | 210 | 203 | 246 | 216 | 233 | 225 | 255 | 260 | 274 | 267 | 334 |
| EPS in Rs | 16.24 | 15.24 | 16.39 | 15.82 | 19.68 | 17.33 | 18.64 | 18.03 | 20.44 | 20.83 | 21.91 | 21.35 | 26.75 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,474 | 1,749 | 1,983 | 2,126 | 2,055 | 2,588 | 2,890 | 3,341 | 3,743 | 4,209 | 4,648 | 5,453 | 5,776 |
| Expenses | 968 | 1,155 | 1,292 | 1,467 | 1,489 | 1,904 | 1,889 | 2,408 | 2,934 | 3,037 | 3,379 | 3,953 | 4,309 |
| Operating Profit | 505 | 594 | 691 | 658 | 567 | 683 | 1,001 | 933 | 808 | 1,172 | 1,269 | 1,500 | 1,467 |
| OPM % | 34% | 34% | 35% | 31% | 28% | 26% | 35% | 28% | 22% | 28% | 27% | 28% | 25% |
| Other Income | 8 | 14 | 20 | 24 | 21 | 88 | 24 | 112 | 74 | 85 | 85 | 67 | 217 |
| Interest | 6 | 5 | 1 | 0 | 1 | 12 | 8 | 10 | 6 | 7 | 21 | 16 | 14 |
| Depreciation | 52 | 44 | 61 | 60 | 72 | 96 | 116 | 125 | 131 | 135 | 144 | 173 | 176 |
| Profit before tax | 456 | 559 | 648 | 623 | 514 | 664 | 900 | 909 | 745 | 1,114 | 1,189 | 1,378 | 1,493 |
| Tax % | 32% | 26% | 22% | 25% | 25% | 30% | 27% | 22% | 21% | 27% | 23% | 23% | |
| Net Profit | 310 | 416 | 507 | 469 | 387 | 468 | 654 | 713 | 588 | 816 | 920 | 1,056 | 1,135 |
| EPS in Rs | 23.47 | 31.49 | 38.40 | 35.50 | 29.56 | 35.73 | 50.38 | 55.63 | 45.89 | 63.70 | 73.68 | 84.52 | 90.84 |
| Dividend Payout % | 17% | 17% | 23% | 0% | 20% | 24% | 13% | 11% | 15% | 79% | 38% | 33% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 13.0% | 14.0% | 12.0% |
| Profit CAGR | 24.0% | 12.0% | 10.0% |
Shareholding Pattern
Promoters66.26%
FIIs8.86%
DIIs17.50%
Public7.38%
Promoters66.25%
FIIs8.53%
DIIs17.90%
Public7.32%
Promoters66.25%
FIIs7.97%
DIIs18.58%
Public7.20%
Promoters66.25%
FIIs8.26%
DIIs18.36%
Public7.14%
Promoters63.49%
FIIs7.68%
DIIs21.80%
Public7.03%
Promoters66.11%
FIIs10.00%
DIIs15.52%
Public7.91%
Promoters66.22%
FIIs8.54%
DIIs17.48%
Public7.76%
Promoters66.26%
FIIs8.86%
DIIs17.48%
Public7.38%
Promoters66.25%
FIIs8.26%
DIIs18.36%
Public7.14%
Promoters63.49%
FIIs7.68%
DIIs21.80%
Public7.03%
AJANTPHARM
Holdings Analysis
Key strengths & risk signals
76
Overall
85
Fundamental
68
Technical
Risks (2)
RECOVERY MODE! Current price (3410.1) above 200-day but below 50-day.
WEAK MOMENTUM! Limited price growth - -4.8% (1 week), -3.5% (1 month), 1.8% (3 months).
Strengths (4)
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
BULLISH TREND! 50-day average (3549.4) is above 200-day average (3136.6) - positive signal.
GOOD YEAR! Stock gained 41.1% in the last year.
LOW VOLATILITY! Beta of 0.20 - stable stock, less market risk.
Fundamental & Technical Analysis
76Overall
85Fundamental
68Technical
Fundamental Breakdown
Growth Quality
26/30
Revenue CAGR: 13.4% (GOOD, 11/15). Profit CAGR: 21.6% (EXCELLENT, 15/15).
Profit Margin
6/10
GOOD EFFICIENCY! 19.6% profit margin - above average profitability.
PEG Valuation
8/10
FAIRLY VALUED! PEG of 1.74 indicates reasonable valuation.
Dividend Yield
5/10
LOW DIVIDEND! 1.86% yield - minimal income contribution.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.01 - excellent financial health.
Public Holding
20/20
VERY LESS PUBLIC HOLDING! 7.78% public ownership - strong promoter/institutional control.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (3549.4) is above 200-day average (3136.6) - positive signal.
Price Position
2/10
RECOVERY MODE! Current price (3410.1) above 200-day but below 50-day.
Trend Pattern
10/20
BREAKDOWN! Stock has broken below support levels - weakness present.
52W Performance
10/10
GOOD YEAR! Stock gained 41.1% in the last year.
Volume Sentiment
20/30
BULLISH SENTIMENT! In last 30 days: 12 up days, 18 down days. Avg volume on up days: 99,330 vs down days: 84,107. Ratio: 1.18x
RSI
3/5
NEUTRAL! RSI at 40.6 - balanced momentum.
52W Range
4/5
UPPER HALF! Trading at 72.7% of 52W range - positive territory.
Momentum
2/5
WEAK MOMENTUM! Limited price growth - -4.8% (1 week), -3.5% (1 month), 1.8% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.20 - stable stock, less market risk.
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AJANTPHARM | ₹3,410.10 | 37.6 | 19.6% | 13.4% | 21.6% | +41.1% | 76 | BREAKDOWN | +30.9% | +25.3% | +24.8% | +14.4% |
| IPCALAB | ₹1,915.40 | 37.1 | 12.9% | 15.5% | 34.3% | +45.3% | 84 | BOUNCE FROM SUPPORT | +72.3% | +34.4% | +20.8% | +16.7% |
| EMCURE | ₹1,833.50 | 34.4 | 10.4% | 15.4% | 20.2% | +34.8% | 81 | BREAKDOWN | +42.0% | +20.8% | +22.8% | +4.5% |
| GLAND | ₹3,061.80 | 44.7 | 16.8% | 21.3% | 9.6% | +63.8% | 83 | BREAKOUT | +47.1% | -13.6% | +19.6% | +3.3% |
| WOCKPHARMA | ₹1,996.40 | 79.3 | 11.2% | 7.8% | – | +43.1% | 58 | CONSOLIDATION | -217.8% | -36.1% | +25.9% | -3.7% |
| ABBOTINDIA | ₹26,000.00 | 34.2 | 23.1% | 9.0% | 17.8% | -13.4% | 68 | APPROACHING RESISTANCE | +17.1% | +8.5% | +4.3% | +6.1% |
| NEULANDLAB | ₹20,890.00 | 53.8 | 21.0% | 18.5% | 30.6% | +28.8% | 73 | BREAKDOWN | +962.6% | -30.6% | +119.1% | -17.4% |
| PPLPHARMA | ₹196.90 | – | -3.4% | 7.6% | – | -2.6% | 57 | BOUNCE FROM SUPPORT | -15.1% | +688.6% | +17.4% | -17.5% |
Data from TradeAlone · Updated daily
